GSK Wellbutrin XL Has Captured Half Of Total Bupropion Market
This article was originally published in The Pink Sheet Daily
Executive Summary
Wellbutrin XL holds 49.6% share of new scripts written for Wellbutrin brand and generic equivalents, Biovail reports. Biovail revenues from product jump to $79.1 mil. in quarter, helped by move up to next tier of pricing in supply agreement with GSK.